XNK Therapeutics, a Sweden-based immunotherapy company, has received scientific recommendation from the European Medicines Agency’s (EMA) Committee for Advanced Therapies for its product Evencaleucel.

Evencaleucel is classified as a Somatic Cell Therapy Medicinal Product.

The classification places Evencaleucel within the category of Advanced Therapy Medicinal Products. The platform utilised by XNK to manufacture the product is designed to produce autologous natural killer (NK) cell-based drug candidates.

The candidates are developed to act on malignant ailments, both as mono and combination therapies.

The platform features a closed manufacturing system, which is pivotal for developing NK cell-based products.

The manufacturing process involves the careful expansion and activation of NK cells derived from the peripheral blood of cancer patients.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

XNK has a pipeline that includes treatments for both haematological malignancies and solid tumours.

Evencaleucel is the company’s most advanced product and is currently undergoing Phase II clinical trials, evaluating the therapy along with isatuximab, a CD38 antibody, to treat multiple myeloma.

Another asset, XNK02, is in advanced preclinical studies in partnership with the MD Anderson Cancer Center to potentially treat acute myeloid leukaemia.

XNK03, aimed at treating bladder cancer, is in preclinical studies in partnership with the Karolinska University Hospital.

Supporting XNK Therapeutics’ innovative work is a team that includes experts in NK cell research.

The company also benefits from an approved in-house good manufacturing practice facility.

XNK Therapeutics chief medical officer Peter Hovstadius stated: “We are very pleased with EMA’s scientific recommendation. This is a necessary step in our regulatory approval journey and will make future interactions easier with the authorities.”

Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva.

Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.